Navigation Links
ULURU Inc. Reports First Quarter 2008 Financial Results
Date:5/12/2008

iew

Commenting on the financial results, Kerry P. Gray, President and CEO stated, "The first quarter operating results are in line with our operating plan. With the launch of Altrazeal(TM), the associated production scale-up expense, and the investment in establishing our commercial organization, we had projected a significant increase in our operating expenses to support these activities. During the upcoming quarters, we will continue to invest in Altrazeal(TM), both in increasing our commercial activities with the hiring off our sales force and in product development for a silver-containing product line extension. The cash impact of these investments is projected to be offset by licensing income, from both existing agreements and planned new agreements."

"During the first quarter, the focus of our organization has been on the launch of Altrazeal(TM). Significant efforts have been devoted to both the commercial scale-up and developing the promotional strategy for the product. The production scale-up was achieved at a scale double that which was originally planned with the potential to increase this by double again. This will have a very favorable impact on the projected product cost for Altrazeal(TM). The market research, which was completed in April 2008, clearly identified the market needs and where Altrazeal(TM) should be positioned. Also, this research was designed to provide data on product pricing which clearly indicates the potential for a premium priced wound dressing product."

Mr. Gray continued, "We are entering an extremely exciting growth phase of the Company. The Company has been converted from a development focused organization to a commercial operation over the past four months. The market research and response from key opinion leaders to Altrazeal(TM) has been very positive. As our first wound dressing product goes to market, our product development efforts are now focused on the next generation wound dressing product, a silver
'/>"/>

SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
4. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. Reports Third Quarter 2007 Results
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
8. ULURU Inc. Announces Odd-Lot Buy Back Offer
9. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
10. Novadaq Reports Financial Results for the First Quarter of 2008
11. Isis Reports Financial Results and Highlights for First Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)..., Dec. 2 To support medication-sa...um (UHC) and Safecor Health, LLC, announced today ...ment for bar-coded pharmaceutical repackaging serv..., , "UHC is very pleased with the addition ...f agreements and is excited to embark on a partner...
(Date:12/2/2008)...Prevention, Shedding, or Sharing Costs as Key , ...-- A New Center for State and Local Government Exc...etiree health care plans and their need to contain...rican States examines how state administrators pe...its to central human resources (HR) goals; how the...
(Date:12/2/2008)...o 70 Cities and Regions by 2010 , , PRINCET... first investment of a new $44 million initiative,...rded grants of up to $400,000 to nine communities ...s for its most ambitious effort yet to reverse the...ids, Healthy Communities will support local actio...
(Date:12/2/2008)... aprotinin, a drug commonly used to control blood ...ared with lysine analogues, according to a study ...e published in the January 20th issue of CMAJ . ... panel will meet to decide on aprotinin use. The s...ting. , The study, a systematic review of 49 ra...
Breaking Medicine News(10 mins):Health News:UHC and Safecor Health Announce Multi-Year Agreement for Repackaging Bar-Coded Medications 2Health News:States View Limits on Retiree Health Benefits 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 4
...o scientists Vivian Cheung and Warren Ewens from t...isorders that are recessively inherited. Gene exp...ould differ significantly and this new diagnostic ...echnology to identify differences in genome-wide e...
...ing cattle with many growth hormones that are extr... among EU nations that import beef, necessitating ...expert and a pharmaceutical chemist, John Verrall ...ts of consuming beef from cattle that have been in...
...ers, a woman who lost her husband to AIDS and is n...in her Bihar home. Premila Devi, 40, from Tilaei ...ing into a well Saturday, just a few months after ...d of AIDS. "She was upset by the way her family m...
... babies’ to be overweight, which is thought to be ...’ diet during pregnancy. A study that analyzed nea... UK, the Scottish babies’ weight scored the highes...tuation can be remedied if pregnant women were mad...
Other Medicine News:Health News:New Diagnostic Tool Uncovered Gene Expression Patterns in Recessive Genetic Disorders 2
(Date:12/1/2008)...ARD, Denmark, December 1 ...with the intent to procure an MVA-based,third ge...ment Services,Canada, on behalf of the Canadian D...ract to Bavarian Nordic for the delivery of IMVAMU... use IMVAMUNE(R) as part of the,country,s bio-pre...
(Date:11/30/2008)...ec. 1 Abnormalities in ...in children with autism spectrum disorder by using...y presented today at the annual meeting of the Rad..., "Using MEG, we can record the tiny magnetic fi...aid Timothy Roberts, Ph.D., vice chair of research...
(Date:11/26/2008)...information density, automation and intelligent cl...trasound to an all new level , , CHICAGO, I...Healthcare ( www.siemens.com/healthcare ) highli...Scanner (ABVS)(1), the world,s first multi-use, a...4th Scientific Assembly and Annual Meeting of the ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 Proteol...nt of novel therapeutics that target,protein degr..., today,announced that data from two ongoing Phas...eloma will be presented at the upcoming 50th Annua...ASH). Carfilzomib is the first in a new class,of...
Breaking Medicine Technology:The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 20824 1Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 20824 2Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 1Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 2Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 3Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 4Bamboo instant houses will soon shelter Sichuan quake victims 3504 1Bamboo instant houses will soon shelter Sichuan quake victims 3504 2Is tap water safe for expectant mothers 3F 20821 1Is tap water safe for expectant mothers 3F 20821 2
...therapeutic approach for the treatment,of early an... 2007 /PRNewswire-FirstCall/ - AEterna,Zentaris In...,focused on endocrine therapy and oncology, today ...ts growth hormone-releasing,hormone (GHRH) antagon...ciation for Cancer Research (AACR) Annual Meeting ...
...pr 16, 2007 - Arsenic, a naturally,occurring eleme...r,2,000 years, and even now remains a venerable co..., Today, due in measure to the efforts of investig...ancer Research Foundation,s,(SWCRF) "Institute Wit...ed in therapy for the treatment of certain types o...
Other Medicine Technology:AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 2Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 3
For determination of HDL-cholesterol in serum and plasma. For Hitachi 717. Specific immunochemical inhibition of non-HDL-lipoproteins. Excellent correlation with established reference methods. Endpoi
Cholesterol/HDL Standard 50 mg/dl.
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included.
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L
Medicine Products: